MedTrace Logo

Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD

NCT01128179 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2021-06-09

Study results available
· View outcomes & findings →

Summary

To assess the effects of 12 weeks of treatment with lanthanum carbonate compared with placebo on serum intact Fibroblast Growth Factor 23 (FGF23) levels.

Conditions

Interventions

DRUG

Lanthanum carbonate

1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks

DRUG

Placebo

Matching placebo chewable tablets administered 3 times a day for 12 weeks

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-06
Primary Completion
2012-04-16
Completion
2012-04-16

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01128179 on ClinicalTrials.gov